Etoposide + cytarabine plus granulocyte colony-stimulating factor mitigates daratumumab-associated impairment on stem cell mobilization in newly diagnosed multiple myeloma

Key Points

• Etoposide and cytarabine treatment enhances stem cell mobilization outcomes, reducing issues caused by daratumumab.
• The study reports a significant improvement in stem cell mobilization, with a key focus on newly diagnosed multiple myeloma.
• Observational analysis compares the effectiveness of etoposide and cytarabine plus granulocyte colony-stimulating factor versus standard treatment.
• These findings suggest the potential for better stem cell collection strategies in multiple myeloma therapy.